• Citer

Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: The D:A:D study

par Bruyand, Mathias;Ryom, Lene;Shepherd, Leah;Fätkenheuer, Gerd;Grulich, Andrew;Reiss, Peter;De Wit, Stéphane ;d'Arminio Monforte, Antonella;Furrer, Hansjakob;Pradier, Christian;Lundgren, Jens D;Sabin, Caroline
Référence Journal of acquired immune deficiency syndromes, 68, 5, page (568-577)
Publication Publié, 2015-04

Article révisé par les pairs

• Détails
• Contenu

Titre:	Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: The D:A:D study
Auteur:	Bruyand, Mathias; Ryom, Lene; Shepherd, Leah; Fätkenheuer, Gerd; Grulich, Andrew; Reiss, Peter; De Wit, Stéphane; d'Arminio Monforte, Antonella; Furrer, Hansjakob; Pradier, Christian; Lundgren, Jens D; Sabin, Caroline
Informations sur la publication:	Journal of acquired immune deficiency syndromes, 68, 5, page (568-577)
Statut de publication:	Publié, 2015-04
Sujet CREF:	Pharmacologie
	Pathologie maladies infectieuses
Mots-clés:	antiretroviral therapy
	cancer
	HIV
	risk
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1525-4135
	info:doi/10.1097/QAI.0000000000000523
	info:scp/84925089152
	info:pmid/25763785